Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings

References

• Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 2005;23:2606-17
   PubMed Web of Science ®Google Scholar
• Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004;61:392-405
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. KDOQI clinical practice guidelines for anemia of chronic kidney disease. Am J Kidney Dis 2006;47(5 Suppl 3):S33-S53
   Web of Science ®Google Scholar
• Johnson DW. Evidence-based guide to slowing the progression of early renal insufficiency. Inter Med J 2004;34:50-7
   Google Scholar
• Spence RK. Medical and economic impact of anemia in hospitalized patients. Am J Health Syst Pharm 2007;64(16 Suppl 11):S3-S10
   PubMedGoogle Scholar
• Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopa Med Prim Care 2007;1:14
   PubMedGoogle Scholar
• National Kidney Foundation. KDOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 2001;37(1 Suppl):S182-238
   PubMed Web of Science ®Google Scholar
• Procrit (epoetin alfa) prescribing information. Raritan, NJ: Ortho Biotech Products, L.P., 2011
   Google Scholar
• Aranesp (darbepoetin alfa) prescribing information. Thousand Oaks, CA: Amgen, Inc., 2011
   Google Scholar
• Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Nat Cancer Inst 2002;94:1211-20
   PubMed Web of Science ®Google Scholar
• National Anemia Action Council. ESA Drugs treat anemia by stimulating red blood cell production. April 8, 2009. [Online]. http://www.anemia.org/patients/feature-articles/content.php?contentid=000379&sectionid=00015. Accessed May 7, 2010
   Google Scholar
• Roger SD. Extended administration of erythropoiesis-stimulating agents for optimising the management of renal anaemia: what is the evidence? Int J Clin Pract 2008;62:1413-22
   PubMed Web of Science ®Google Scholar
• Spivak JL, Gascón P, Ludwig H. Anemia management in oncology and hematology. Oncologist 2009;14(1 Suppl):43-56
   PubMedGoogle Scholar
• Vekeman F, McKenzie RS, Lefebvre P, et al. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. Am J Health-Syst Pharm 2007;64:1943-9
   PubMed Web of Science ®Google Scholar
• Vekeman F, McKenzie RS, Bookhart BK. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database. J Med Econ 2009;12:1-8
   PubMedGoogle Scholar
• Papatheofanis F, Smith C, Mody S, et al. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study. Am J Ther 2007;14:322-7
   PubMedGoogle Scholar
• Lefebvre P, Gosselin A, McKenzie RS, et al. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr Med Res Opin 2006;22:1623-31
   PubMed Web of Science ®Google Scholar
• Mark TL, McKenzie RS, Fastenau J, et al. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Curr Med Res Opin 2005;21:1347-54
   PubMed Web of Science ®Google Scholar
• Duh MS, Mody SH, McKenzie RS, et al. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Clin Ther 2006;28:1443-50
   PubMed Web of Science ®Google Scholar
• Duh MS, Mody SH, McKenzie RS, et al. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed-care organizations. Drugs Aging 2006;23:969-76
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). Washington, DC: Department of Health & Human Services [Online]. 2007. https://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=203. Accessed May 7, 2010
   Google Scholar
• National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Clinical practice guidelines and clinical practice recommendation for anemia in chronic kidney disease published: 2007 update of hemoglobin target [Online]. http://www.kidney.org/professionals/KDOQI/guidelines_anemiaUP/index.htm. Accessed May 7, 2010
   Google Scholar
• U.S. Renal Data System. USRDS 2009 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009. [Online]. http://www.usrds.org/atlas.htm. Accessed May 7, 2010
   Google Scholar
• Averill RF, Goldfield G, Hughes JS, et al. All patient refined diagnosis-related groups (APR-DRGs) version 20.0: methodology overview. Wallington, CT: 3M Health Information Systems [Online], 2007. http://www.hcup-us.ahrq.gov/db/nation/nis/APR-DRGsV20MethodologyOverviewandBibliography.pdf. Accessed May 7, 2010
   Google Scholar
• Thomson PDS. ReadyPrice software. Last update: April 2010
   Google Scholar
• US Department of Health & Human Services, Centers for Medicare and Medicaid Services (CMS). ASP: Average Sales Price (ASP) per “Apr 10 ASP Pricing File 031811”. http://www.cms.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPrice/downloads/April_2010_ASP_Pricing_File.zip. Accessed November 16, 2011
   Google Scholar
• Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-2000
   PubMed Web of Science ®Google Scholar
• Papatheofanis FJ, McKenzie RS, Mody SH, et al. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin 2006;22:837-42
   PubMed Web of Science ®Google Scholar
• Hymes J, Bickimer T, Jackson JH, et al. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa. Curr Med Res Opin 2007;23:1931-7
   PubMed Web of Science ®Google Scholar
• Daniel G, Hurley F, Whyte JL, et al. Use and cost of erythropoiesis-stimulating agents in patients with cancer. Curr Med Res Opin 2009;25:1775-84
   PubMed Web of Science ®Google Scholar
• Kruep EJ, Basskin LE. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. Am J Health-Syst Pharm 2005;62:2597-603
   PubMed Web of Science ®Google Scholar